JP2010536858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536858A5 JP2010536858A5 JP2010521913A JP2010521913A JP2010536858A5 JP 2010536858 A5 JP2010536858 A5 JP 2010536858A5 JP 2010521913 A JP2010521913 A JP 2010521913A JP 2010521913 A JP2010521913 A JP 2010521913A JP 2010536858 A5 JP2010536858 A5 JP 2010536858A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- effective amount
- therapeutically effective
- patient
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 230000037396 body weight Effects 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims 2
- 102100036509 Erythropoietin receptor Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95739607P | 2007-08-22 | 2007-08-22 | |
| US98975807P | 2007-11-21 | 2007-11-21 | |
| PCT/US2008/070943 WO2009025958A1 (en) | 2007-08-22 | 2008-07-23 | Erythropoietin rceptor peptide formulations and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010536858A JP2010536858A (ja) | 2010-12-02 |
| JP2010536858A5 true JP2010536858A5 (enExample) | 2011-10-20 |
Family
ID=40194013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521913A Pending JP2010536858A (ja) | 2007-08-22 | 2008-07-23 | エリスロポエチン受容体ペプチド製剤及び用途 |
| JP2010521912A Pending JP2010536857A (ja) | 2007-08-22 | 2008-07-23 | エリスロポエチン受容体ペプチドの製剤及び使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521912A Pending JP2010536857A (ja) | 2007-08-22 | 2008-07-23 | エリスロポエチン受容体ペプチドの製剤及び使用 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2195002A4 (enExample) |
| JP (2) | JP2010536858A (enExample) |
| WO (2) | WO2009025958A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9422338B2 (en) | 2011-05-19 | 2016-08-23 | Epodose Llc | Compounds that bind to the erythropoietin receptor |
| WO2015183545A1 (en) * | 2014-05-28 | 2015-12-03 | The Board Of Regents Of The University Of Texas System | Novel compounds supports hematopoietic stem cells and red blood cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ543935A (en) * | 2003-05-12 | 2008-06-30 | Affymax Inc | Peptides that bind to the erythropoietin receptor |
| MXPA05012316A (es) * | 2003-05-12 | 2006-04-18 | Affymax Inc | Peptidos novedosos que se unen al receptor de la eritropoyetina. |
| US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7919461B2 (en) * | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US8343953B2 (en) * | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
-
2008
- 2008-07-23 WO PCT/US2008/070943 patent/WO2009025958A1/en not_active Ceased
- 2008-07-23 EP EP08796513A patent/EP2195002A4/en not_active Withdrawn
- 2008-07-23 WO PCT/US2008/070926 patent/WO2009025957A1/en not_active Ceased
- 2008-07-23 JP JP2010521913A patent/JP2010536858A/ja active Pending
- 2008-07-23 JP JP2010521912A patent/JP2010536857A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6738376B2 (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
| JP2010540555A5 (enExample) | ||
| US20150342872A1 (en) | Use of Paclitaxel Particles | |
| JP2009536191A5 (enExample) | ||
| JP2006507308A5 (enExample) | ||
| JP2008542399A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| US20140356315A1 (en) | Triblock copolymer and use therefor | |
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| JP2017025086A (ja) | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 | |
| JP2012503602A5 (enExample) | ||
| Colleoni et al. | A phase II study of mitoxantrone combined with beta‐interferon in unresectable hepatocellular carcinoma | |
| JP2010536858A5 (enExample) | ||
| EP1383517A1 (en) | Use of cationic dextran derivatives for protecting dose-limiting organs | |
| RU2440113C2 (ru) | Фармацевтическая композиция для инъекционного особенно целенаправленного местного применения | |
| CN117959315A (zh) | 化合物pgg作为krasg12d抑制剂mrt1133的增效剂联合治疗胰腺癌的应用 | |
| CN1168452C (zh) | 甲氧基吗啉代阿霉素在制备治疗肝肿瘤的药物方面的应用 | |
| CN115590974A (zh) | 功能化靶向制剂及其制备方法、应用 | |
| CN102083428A (zh) | 采用长时间连续输液Belinostat进行治疗的方法 | |
| AU2013226944B2 (en) | Inhibitory agent for body cavity fluid accumulation | |
| JP2010521488A5 (enExample) | ||
| CN120393051A (zh) | 一种基于介孔聚多巴胺的靶向纳米系统及其制备方法和应用 | |
| RU2406539C2 (ru) | Способ лечения хронической почечной недостаточности | |
| WO2023182317A1 (ja) | ボロン酸含有修飾ポリロタキサン | |
| JPWO2020047113A5 (enExample) |